Inversago Pharma
Dr. John Kastelein is the founder and CSO of New Amsterdam Pharma and part of the Executive Board. He's also an Emeritus Professor of Medicine at the Department of Vascular Medicine at the Academic Medical Center of the University of Amsterdam, where he held the Strategic Chair of Genetics of Cardiovascular Disease.
He has published over 1,520 research papers in peer-reviewed journals, including Nature Genetics, The Lancet, New England Journal of Medicine, JAMA, and Circulation, and had a Hirsch index of 122 in January 2020. His citations reached Over 680 in 2020 and in total over 74,800.
Dr. Kastelein is a member of steering committees of numerous lipid-lowering and cardiovascular intervention trials. His main interest is in the development of novel therapies for cardiovascular diseases and the genetic basis of dyslipidemia. He's also CEO of the Vascular Research Network (VRN), a site maintenance organization comprised of 50 hospitals in the Netherlands, involved in clinical trials for cardiometabolic diseases.
This person is not in the org chart
This person is not in any offices
Inversago Pharma
A specialized, preclinical-stage biotech company, Inversago Pharma develops new generations of peripherally-restricted cannabinoid-1 receptor (CB1) inverse agonists/ antagonists for the treatment of Prader-Willi Syndrome, diabetes, obesity and other metabolic disorders such as non-alcoholic steatohepatitis (NASH).